DBVT, DBVTF · CIK 0001613780 · operating
DBV Technologies operates as a clinical-stage biopharmaceutical company focused on epicutaneous immunotherapy, a delivery method that applies therapeutic compounds to intact skin. Headquartered in Châtillon, France, the company develops treatments targeting allergic and inflammatory conditions. Its most advanced program, Viaskin Peanut, completed Phase 3 clinical trials for peanut allergy treatment. Viaskin Milk is in Phase 1/2 development for cow's milk protein allergy and eosinophilic esophagitis. The company maintains a pipeline of earlier-stage research programs addressing respiratory syncytial virus, inflammatory bowel disease, celiac disease, and type 1 diabetes.
The Viaskin platform represents the company's core technology, designed to enable immune tolerance through epicutaneous application. DBV Technologies also collaborates with Nestlé Health Science on MAG1C, an atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers.
The company operates with approximately 117 full-time employees and maintains a primarily European operational footprint, with incorporation and headquarters in France. As a clinical-stage entity, DBV Technologies has not yet generated product revenues from approved therapeutics.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-1.17 | $-1.17 | -53.9% | |
| 2023 | $-0.76 | $-0.76 | +38.7% | |
| 2022 | $-1.24 | $-1.24 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — |